Nothing Special   »   [go: up one dir, main page]

UA97559C2 - Комплекс нуклеїнової кислоти і композиція для доставки нуклеїнової кислоти - Google Patents

Комплекс нуклеїнової кислоти і композиція для доставки нуклеїнової кислоти

Info

Publication number
UA97559C2
UA97559C2 UAA201007049A UAA201007049A UA97559C2 UA 97559 C2 UA97559 C2 UA 97559C2 UA A201007049 A UAA201007049 A UA A201007049A UA A201007049 A UAA201007049 A UA A201007049A UA 97559 C2 UA97559 C2 UA 97559C2
Authority
UA
Ukraine
Prior art keywords
nucleic acid
cell
complex
acid complex
delivery composition
Prior art date
Application number
UAA201007049A
Other languages
English (en)
Russian (ru)
Inventor
Хірофумі Такеуті
Юіті Тозука
Ясуюкі Хіра
Хідеказу Тойобуку
Original Assignee
Оцука Фармасьютікал Ко., Лтд.
Хірофумі Такеуті
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оцука Фармасьютікал Ко., Лтд., Хірофумі Такеуті filed Critical Оцука Фармасьютікал Ко., Лтд.
Publication of UA97559C2 publication Critical patent/UA97559C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Винахід стосується комплексу нуклеїнової кислоти, що має низьку токсичність і високий ступінь безпеки, який здатний стійко підтримувати вміст нуклеїнової кислоти, наприклад, siRNA або подібної, у клітині, а також стосується композиції для доставки нуклеїнової кислоти, яка здатна ефективно доставляти комплекс нуклеїнової кислоти в клітину. Комплекс нуклеїнової кислоти включає нуклеїнову кислоту і сильно розгалужений циклічний декстрин, який являє собою глюкан зі ступенем полімеризації 50-5000, що включає внутрішній розгалужений циклічний структурний фрагмент, утворений α-1,4-глюкозидними зв'язками і як мінімум одним α-1,6-глюкозидним зв'язком, і зовнішній розгалужений структурний фрагмент, зв'язаний із внутрішнім розгалуженим циклічним структурним фрагментом. Крім того, безпека та ефективність введення в клітину, а також стійкість нуклеїнової кислоти в клітині можуть бути додатково поліпшені, якщо у ролі носія для введення комплексу нуклеїнової кислоти в клітину застосовують носій, що включає (А) діацилфосфатиділхолін, (В) холестерин і/або його похідне і (С) первинний аліфатичний амін.
UAA201007049A 2007-11-08 2008-06-11 Комплекс нуклеїнової кислоти і композиція для доставки нуклеїнової кислоти UA97559C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007291317 2007-11-08
PCT/JP2008/070642 WO2009061003A2 (en) 2007-11-08 2008-11-06 Nucleic acid complex and nucleic acid delivery composition

Publications (1)

Publication Number Publication Date
UA97559C2 true UA97559C2 (uk) 2012-02-27

Family

ID=40303461

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201007049A UA97559C2 (uk) 2007-11-08 2008-06-11 Комплекс нуклеїнової кислоти і композиція для доставки нуклеїнової кислоти

Country Status (28)

Country Link
US (1) US8338584B2 (uk)
EP (1) EP2217208B1 (uk)
JP (1) JP5340282B2 (uk)
KR (1) KR101567108B1 (uk)
CN (1) CN101854918B (uk)
AR (1) AR069224A1 (uk)
AT (1) ATE522201T1 (uk)
AU (1) AU2008325504B2 (uk)
BR (1) BRPI0819187A2 (uk)
CA (1) CA2704236C (uk)
CO (1) CO6280469A2 (uk)
CY (1) CY1112029T1 (uk)
DK (1) DK2217208T3 (uk)
ES (1) ES2369869T3 (uk)
HK (1) HK1142278A1 (uk)
HR (1) HRP20110698T1 (uk)
IL (1) IL205237A0 (uk)
MX (1) MX2010005094A (uk)
MY (1) MY149917A (uk)
NZ (1) NZ584841A (uk)
PL (1) PL2217208T3 (uk)
PT (1) PT2217208E (uk)
RU (1) RU2465009C2 (uk)
SI (1) SI2217208T1 (uk)
TW (1) TWI426922B (uk)
UA (1) UA97559C2 (uk)
WO (1) WO2009061003A2 (uk)
ZA (1) ZA201002845B (uk)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI428135B (zh) 2007-03-26 2014-03-01 Hirofumi Takeuchi And a carrier composition for quick-acting nucleic acid delivery
AR083445A1 (es) 2010-10-14 2013-02-27 Univ Mie siARN CONTRA LA FIBROSIS
CA2822161C (en) 2010-12-29 2018-05-29 Philipp Hadwiger Small molecule conjugates for intracellular delivery of nucleic acids
PT2825565T (pt) 2012-03-15 2019-07-10 Acraf Polímeros catiónicos à base de glicogénio
JPWO2019131727A1 (ja) * 2017-12-27 2021-02-12 コニカミノルタ株式会社 医薬の評価方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01238537A (ja) * 1988-03-18 1989-09-22 Toyo Jozo Co Ltd 肝障害治療剤
JP3150266B2 (ja) * 1994-04-01 2001-03-26 江崎グリコ株式会社 環状構造を有するグルカンおよびその製造方法
JP3107358B2 (ja) 1994-09-13 2000-11-06 江崎グリコ株式会社 環状構造を有するグルカンおよびその製造方法
US6248566B1 (en) * 1994-09-13 2001-06-19 Ezaki Glico Co., Ltd. Glucan having cyclic structure and method for producing the same
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5827697A (en) * 1995-03-31 1998-10-27 Ezaki Glico Co., Ltd. Process for preparing glucans having a cyclic structure
US20030092180A1 (en) 2001-08-27 2003-05-15 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
JPH11292795A (ja) 1998-04-02 1999-10-26 Yamanouchi Pharmaceut Co Ltd Ｈｉｖコファクター抑制剤
EP2298728A1 (en) 1998-11-12 2011-03-23 Life Technologies Corporation Transfection reagents
CA2465860A1 (en) * 2001-11-02 2004-04-22 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference
RU2289585C2 (ru) * 2002-02-04 2006-12-20 Корикса Корпорейшн Новые аминоалкилглюкозаминидфосфатные соединения, иммуностимулирующая фармацевтическая композиция, их содержащая, и способ индуцирования иммунного ответа
US20040204420A1 (en) * 2002-08-05 2004-10-14 Rana Tariq M. Compounds for modulating RNA interference
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
US7780873B2 (en) * 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
US20060228420A1 (en) * 2005-03-15 2006-10-12 Queen Mary & Westfield College Pharmaceutical compositions comprising microparticles for delivery into neurons

Also Published As

Publication number Publication date
ATE522201T1 (de) 2011-09-15
CN101854918A (zh) 2010-10-06
BRPI0819187A2 (pt) 2015-05-05
RU2010123168A (ru) 2011-12-20
WO2009061003A3 (en) 2010-05-27
US20100305190A1 (en) 2010-12-02
AU2008325504B2 (en) 2013-03-07
WO2009061003A2 (en) 2009-05-14
TWI426922B (zh) 2014-02-21
HRP20110698T1 (hr) 2011-10-31
KR20100092007A (ko) 2010-08-19
MY149917A (en) 2013-10-31
PT2217208E (pt) 2011-11-08
CY1112029T1 (el) 2015-11-04
ZA201002845B (en) 2011-07-27
PL2217208T3 (pl) 2012-01-31
MX2010005094A (es) 2010-05-27
EP2217208A2 (en) 2010-08-18
RU2465009C2 (ru) 2012-10-27
EP2217208B1 (en) 2011-08-31
NZ584841A (en) 2011-12-22
SI2217208T1 (sl) 2011-11-30
TW200927175A (en) 2009-07-01
IL205237A0 (en) 2010-11-30
ES2369869T3 (es) 2011-12-07
CN101854918B (zh) 2012-11-28
US8338584B2 (en) 2012-12-25
KR101567108B1 (ko) 2015-11-06
CO6280469A2 (es) 2011-05-20
AR069224A1 (es) 2010-01-06
AU2008325504A1 (en) 2009-05-14
DK2217208T3 (da) 2011-10-10
CA2704236C (en) 2015-09-15
HK1142278A1 (en) 2010-12-03
JP5340282B2 (ja) 2013-11-13
JP2011504457A (ja) 2011-02-10
CA2704236A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
MX2022009280A (es) Vacunas de arn contra el coronavirus.
WO2022067130A3 (en) Prime editing guide rnas, compositions thereof, and methods of using the same
EP3333881A3 (en) Dopant gas composition
PH12017501501A1 (en) Compositions and methods for inhibiting expression of tmprss6 gene
MX364707B (es) Conjugados de proteina-agente activo y método para su preparación.
TW200714294A (en) Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
MX352823B (es) Formulaciones de proteinas que contienen aminoacidos.
WO2022221359A8 (en) Epstein-barr virus mrna vaccines
MX2020011807A (es) Composiciones y metodos para inhibir la expresion genica del virus de hepatitis b.
SG195194A1 (en) Nanogels
AU2013334740A8 (en) Stable, low viscosity antibody formulation
EP2633036A4 (en) METHODS OF DIFFERENTIATION FOR THE PRODUCTION OF GLIAL CELL POPULATIONS
MX353409B (es) Método para producir el factor von willebrand (vwf) de alto peso molecular recombinante en cultivo celular.
NZ584048A (en) Lipopeptides for delivery of nucleic acids
MX2010005094A (es) Complejo de acido nucleico y composicion de suministro de acido nucleico.
MX2010003323A (es) Composiciones de poliplex de quitosana-acido nucleico de alta concentracion.
HK1141790A1 (uk)
MX346019B (es) Kit para detectar el virus de la leucemia bovina (blv), y uso del mismo.
MX2022005327A (es) Tintes y composiciones que contienen ciclooctatetraeno..
WO2013019857A3 (en) Method for improving the success rate of hematopoietic stem cell transplants
MY149502A (en) Carrier composition for nucleic acid transport
WO2009006446A3 (en) Methods for cloning small rna species
WO2005094353A3 (en) Methods for production of regulatory t cells and uses thereof
MY151450A (en) Prompt nucleic acid delivery carrier composition
NZ616745A (en) Antisense formulation